LF
LFVN.US Lifevantage Corporation
- Market cap
- USD 63.0M
- P/E
- 23.7x
- P/B
- 1.90x
- ROE
- -2.4%
- Dividend yield
- 3.72%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is LFVN.US undervalued?
Graham numberLFVN.US trades 41.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lifevantage Corporation fundamental analysis
No fundamental analysis for Lifevantage Corporation yet.
Lifevantage Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lifevantage Corporation
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, gut health, and skin and hair care products in the United States and internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to s…
Full company profileLifevantage Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lifevantage Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 199M | 203M | 226M | 233M | 220M | 206M | 213M | 200M | 229M | 183M | 148M |
| Gross Profit | 166M | 168M | 188M | 195M | 182M | 168M | 170M | 159M | 184M | 142M | 112M |
| Operating Income | 4.45M | 10.3M | 9.49M | 15.5M | 17.6M | 7.58M | 4.26M | 4.33M | 12.2M | 6.10M | -544K |
| EBITDA | 5.12M | 11.3M | 11.4M | 19.9M | 20.5M | 7.96M | 7.84M | 7.93M | 15.4M | 8.84M | 2.18M |
| Net Income | 1.61M | 5.76M | 7.43M | 11.5M | 12.9M | 3.12M | 2.54M | 2.94M | 9.81M | 5.07M | -784K |
| EPS | 0.11 | 0.41 | 0.50 | 0.79 | 0.90 | 0.24 | 0.20 | 0.23 | 0.75 | 0.40 | -0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 45.2M | 51.1M | 55.3M | 58.9M | 78.7M | 70.7M | 66.1M | 60.3M | 72.0M | 62.1M | 59.2M |
| Total Liabilities | 30.7M | 29.2M | 28.1M | 25.6M | 41.9M | 39.2M | 31.5M | 34.3M | 37.3M | 28.5M | 25.9M |
| Shareholders' Equity | 14.5M | 21.9M | 27.2M | 33.3M | 36.8M | 31.5M | 34.6M | 26.0M | 34.6M | 33.6M | 33.3M |
| Cash & Short-term Investments | 11.5M | 16.7M | 18.8M | 22.1M | 23.2M | 20.2M | 21.6M | 16.9M | 20.2M | 14.9M | 13.7M |
| Total Debt | 7.44M | 5.41M | 1.45M | 1.18M | 18.2M | 15.8M | 13.1M | 13.6M | 11.7M | 9.87M | 9.40M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 6.60M | 13.3M | 17.8M | 18.3M | 7.96M | 7.96M | 6.83M | 12.2M | 11.9M | 10.2M | 2.13M |
| Capital Expenditure | 1.06M | 4.65M | 2.51M | 2.68M | 1.53M | 1.53M | 3.07M | 2.25M | 1.37M | 3.57M | 4.96M |
| Free Cash Flow | 5.54M | 8.61M | 15.3M | 15.6M | 6.43M | 6.43M | 3.76M | 9.95M | 10.5M | 6.67M | -2.83M |
| Ratios | |||||||||||
| ROE | 11.1% | 26.2% | 27.3% | 34.7% | 35.0% | 9.9% | 7.3% | 11.3% | 28.3% | 15.1% | -2.4% |
| ROA | 3.6% | 11.3% | 13.4% | 19.6% | 16.4% | 4.4% | 3.8% | 4.9% | 13.6% | 8.2% | -1.3% |
| Net Profit Margin | 0.8% | 2.8% | 3.3% | 5.0% | 5.9% | 1.5% | 1.2% | 1.5% | 4.3% | 2.8% | -0.5% |
| Debt to Equity | 0.51x | 0.25x | 0.05x | 0.04x | 0.49x | 0.50x | 0.38x | 0.52x | 0.34x | 0.29x | 0.28x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lifevantage Corporation dividends
- Dividend yield
- 3.72%
- Forward dividend
- 0.20 USD
- Payout ratio
- 46.2%
- Ex-dividend date
- Dec 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 2.34M | 0.18 | 46.2% |
| 2025 | USD 2.07M | 0.16 | 21.1% |
| 2024 | USD 6.94M | 0.53 | 236.3% |
| 2023 | USD 1.59M | 0.13 | 62.4% |
| 2022 | USD 378K | 0.03 | 12.1% |
| 2021 | USD 378K | 0.03 | 2.9% |
| 2020 | USD 653K | 0.04 | 5.7% |
| 2019 | USD 701K | 0.05 | 9.4% |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:7 on Oct 19, 2015.
Who owns Lifevantage Corporation
- Insiders 14.36%
- Institutions 55.47%
- Public & others 30.17%
- Shares outstanding 12.7M
- Free float 8.61M
Top funds holding LFVN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 308K | 2.44% | 0.00% | Sep 2026 |
| Avantis US Small Cap Value ETF | 225K | 1.79% | 0.00% | Oct 2026 |
| DFA U.S. Small Cap I | 72.7K | 0.58% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 55.4K | 0.44% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 33.3K | 0.26% | 0.00% | Oct 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 32.6K | 0.26% | +187.33% | Jun 2026 |
| DFA US Micro Cap I | 26.8K | 0.21% | 0.00% | Sep 2026 |
| EA Bridgeway Omni Small-Cap Value ETF | 23.5K | 0.19% | 0.00% | Oct 2026 |
| Hartford Multifactor Small Cap ETF | 22.9K | 0.18% | 0.00% | Oct 2026 |
| DFA U.S. Core Equity 2 Instl | 21.1K | 0.17% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 18.7K | 0.15% | 0.00% | Sep 2026 |
| Dimensional US Equity Market ETF | 16.8K | 0.13% | 0.00% | Oct 2026 |
| Avantis US Small Cap Equity ETF | 16.7K | 0.13% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 16.0K | 0.13% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 2 ETF | 13.2K | 0.11% | 0.00% | Oct 2026 |
| T. Rowe Price Extended Equity Market Idx | 12.9K | 0.10% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 12.1K | 0.10% | 0.00% | Oct 2026 |
| DFA U.S. Core Equity 1 I | 11.3K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 9.38K | 0.07% | 0.00% | Aug 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 8.58K | 0.07% | 0.00% | Oct 2026 |
Top institutions holding LFVN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Capital Management Corp | 2.31M | 18.33% | +22.84% | Sep 2026 |
| Renaissance Technologies Corp | 630K | 5.01% | -5.86% | Sep 2026 |
| Vanguard Capital Management, LLC | 429K | 3.41% | -0.05% | Jun 2026 |
| BlackRock Inc | 269K | 2.13% | -65.10% | Jun 2026 |
| American Century Companies Inc | 257K | 2.04% | +78.15% | Sep 2026 |
| Dimensional Fund Advisors, Inc. | 239K | 1.90% | -6.61% | Sep 2026 |
| Susquehanna International Group, LLP | 169K | 1.34% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 138K | 1.10% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 121K | 0.96% | -53.74% | Jun 2026 |
| AQR Capital Management LLC | 113K | 0.90% | -27.48% | Jun 2026 |
| The Goldman Sachs Group Inc | 111K | 0.88% | -40.11% | Jun 2026 |
| Citadel Advisors Llc | 99.8K | 0.79% | +30.43% | Jun 2026 |
| Advyzon Investment Management, LLC | 85.8K | 0.68% | -20.71% | Jun 2026 |
| Indivisible Partners | 84.2K | 0.67% | -21.21% | Jun 2026 |
| Perkins Capital Management Inc | 75.5K | 0.60% | 0.00% | Jun 2026 |
| Millennium Management LLC | 70.3K | 0.56% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 65.3K | 0.52% | -28.84% | Jun 2026 |
| Barclays PLC | 64.9K | 0.52% | +6.55% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 64.2K | 0.51% | -4.96% | Jun 2026 |
| Qube Research & Technologies | 54.1K | 0.43% | 0.00% | Jun 2026 |
Lifevantage Corporation company profile
- Company name
- Lifevantage Corporation
- Ticker
- LFVN.US
- Exchange
- USA Stocks
- Listed since
- Oct 5, 2004
- Sector
- Consumer Defensive
- Industry
- Personal Care Products
- Employees
- 209
- Fiscal year end
- June
- Address
- 3300 North Triumph Boulevard, Lehi, UT, United States, 84043
- Phone
- 801 432 9000
- Website
- lifevantage.com
About Lifevantage Corporation
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, gut health, and skin and hair care products in the United States and internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; LifeVantage Daily Wellness, a dietary supplement to strengthen immune health; LifeVantage Rise AM and Reset PM System that provides the body with the right nutrients; LifeVantage D3+, a dietary supplement that provides vitamin D3 and K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular health; P84 System, a product activator consisting of PhytoPower 1 and PhytoPower 2 that contains probiotics, prebiotics, postbiotics, digestive enzymes, and superfood blends designed to support gut health; MindBody GLP-1 System, a dietary supplement that combines two products, MB Core and MB Enhance, which are designed to support weight management and wellness by activating GLP-1 naturally and balancing signals along the gut-brain axis; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. It also provides anti-aging skin care products, such as liquid collagen, facial cleansers, eye cream, moisturizing cream, sunscreen, perfecting lotions, and hand creams, as well as shampoos, nourishing conditioners, and scalp serums under the TrueScience brand name. It sells its products through its website and network of independent consultants. LifeVantage Corporation is based in Lehi, Utah.
Lifevantage Corporation management
5- Mr. Carl A. Aure CPAChief Financial Officer · born 1973
- Ms. Kristen CunninghamChief Sales Officer · born 1984
- Mr. Terrence O. MooreheadPresident, CEO & Director · born 1963
- Mr. Mike EdwardsChief Technology Officer
- Ms. Michelle Oborn-VirchowChief People Officer · born 1980